YHD001 dose level 1

Phase 2Small molecule

YYuhan Corporation

YHD001 dose level 1 is one of 60 small molecule programs targeting Chronic Bronchitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic BronchitisActive, not recruiting

AsthmaActive, not recruiting

Chronic BronchitisPhase 2

Active, not recruiting

AsthmaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Veramyst

GSK

Preclinical

46 2

Xolair

Roche

Preclinical

25 3

Singulair

AstraZeneca

Preclinical

17 4

Nucala

GGlaxo Dba Glaxosmithkline

Preclinical

35 5

Cinqair

Teva

Preclinical

13 6

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

30 7

Asmanex

Novartis

Preclinical

5 8

Celexa

AbbVie

Preclinical

1 9

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

8 10

Spiriva

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Asthma1 trial

Safety and Efficacy of YHD001 in Asthma

Completed·YYuhan Corporation·Phase 2·NCT01424124·56 enrolled

Chronic Bronchitis1 trial

Safety/Tolerability and Efficacy of YHD001 in Patients With Acute and Chronic Bronchitis

Completed·YYuhan Corporation·Phase 2·NCT01420445·118 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for YHD001 dose level 1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — YHD001 dose level 1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for YHD001 dose level 1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yuhan Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: YYuhan Corporation

YHD001 dose level 1

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Asthma1 trial

Chronic Bronchitis1 trial

References

Drug Info

Quick Facts

Related News